Michael Floyd - Nov 1, 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Signature
/s/ Michael Floyd by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Nov 1, 2021
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 05:50 PM
Previous filing
Oct 8, 2021
Next filing
Jan 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Gift $0 -7K -8.98% $0.00 70.9K Mar 31, 2022 Direct F1
holding PCSA Common Stock 66.3K Nov 1, 2021 by Elion Oncology, Inc. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +4.29K +18.81% $0.00 27.1K Nov 1, 2021 Common Stock 4.29K $0.00 Direct F2
transaction PCSA Restricted Stock Units Award $0 +10.7K +39.59% $0.00 37.8K Mar 31, 2022 Common Stock 10.7K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in an transaction exempt from Section 16 reporting.
F2 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.